Key result
NSAID use is linked to a ~16% reduction in CV events.
Why the study?
NSAIDs are common analgesics and treatments for inflammatory disorders, but their cardiovascular safety remains questionable.
Does NSAID use affect the incidence of cardiovascular events and mortality compared to non-NSAID therapies?
Meta-Analysis
Does NSAID use affect the incidence of cardiovascular events and mortality compared to non-NSAID therapies?
This meta-analysis highlights the variable cardiovascular safety profile of different NSAIDs, emphasizing the need for clinicians to balance therapeutic benefits with potential cardiovascular hazards.
Answers are grounded in this paper and cite their sources.
Warrants individualized NSAID selection with CV monitoring; leaves agent-specific risks and net benefit open for targeted trials.
NSAIDs, or nonsteroidal anti-inflammatory medications, are popular and efficient analgesis and frequent mainstay treatements for inflammatory disorders. However, their cardiovascular safety is questionable. The aims of the current study were: (1) to evaluate the comparative cardiovascular efficacy of NSAIDs; (2) to investigate the cardiovascular safety and risks associated with NSAID use; (3) to highlight the importance of alternative therapies for patients who display contraindications to NSAID. A number of digital databases were explored to retrieve relevant studies. These consist of ClinicalTrials.gov, PubMed, Google Scholar, ScienceDirect, etc. The final sample consisted of 17 primary studies.A total of 12/17 (71%) studies advocated the efficacy and safety of NSAIDs. The remaining 2/17 (11%) showed that there was no discernible difference between the NSAID and non-NSAID groups in terms of mortality, cardio-respiratory morbidity, and cardiovascular risk. A forest plot was created using data from eight distinct studies. The results for the incidence of cardiovascular events were found to be statistically significant. The heterogeneity was calculated to be Tau2= 0.15; Chi2=117.67; df=6; I2=95%. The overall effect size was found to be Z=0.08 (p<0.94); the Hazard Ratio was found to be 0.84, CI=95% (CI, 0.72 = 0.98). Certain agents have a higher risk of causing unfavorable cardiovascular events, although other agents might have a safer profile. Clinicians must have this comprehensive knowledge to balance the therapeutic benefits of NSAIDs with any potential cardiovascular hazards when making judgments.
No takes yet. Share an insight, caveat, or question.
Mahmood et al. (2024) conducted a meta-analysis in Inflammatory disorders. NSAIDs vs. non-NSAID groups was evaluated on incidence of cardiovascular events (HR 0.84, 95% CI 0.72-0.98, p=<0.94). NSAID use was associated with a pooled hazard ratio of 0.84 (95% CI 0.72-0.98; p<0.94) for the incidence of cardiovascular events across eight analyzed studies.
Synapse has enriched 10 related papers. Consider them for comparative context: